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HIV-1 isolates exhibit specificity for infection of immortalized T-cell lines and macrophages. The distinct cellular tropisms
have been attributed to expression of coreceptors CXCR4 or CCR5, respectively. However, it is unclear whether or not other
tissue-specific determinants regulate entry. The current study uses a panel of viruses to analyze the relationship between
CCR5 utilization and macrophage infection. Only chimeric viruses with the entire V3 loop from macrophage-tropic isolates,
ADA or SF162, were able to infect macrophages. In contrast, chimeric viruses with smaller portions of the ADA V3 loop or
the V3 loop of SF2, sufficient to allow CCR5 use, were insufficient for macrophage infection. PCR analysis showed that the
defect in macrophage infection of the latter viruses was due to a defect in entry. Moreover, strains capable of infecting
macrophages showed relative resistance to neutralization by anti-CCR5 antibody, 2D7, compared to strains which utilize
CCR5 but are incapable of macrophage infection. © 1999 Academic Press
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Tissue macrophages, Langerhans cells, and micro-
lial cells are infected by HIV-1 and serve as a viral
eservoir (Blauvelt and Katz, 1995; Levy, 1993). Although
ll HIV-1 strains infect peripheral blood mononuclear
ells (PBMCs), most isolates show specificity for immor-
alized T-cell lines or monocyte-derived macrophages
MDMs) in vitro (Gartner et al., 1986; Koyanagi et al.,
987). This cellular tropism is governed in part by the
oreceptor expression pattern of different cell types.
any immortalized T-cells express CXCR4, but not
CR5, and are susceptible to infection only by isolates
hat utilize CXCR4 (Hesselgesser et al., 1998). MDMs
xpress CCR5, which serves as the primary coreceptor
or most HIV-1 isolates. Although CXCR4 also is ex-
ressed on MDMs, it is present in a functionally re-
tricted form, and CCR5 is preferentially utilized (Naif et
l., 1998; Yi et al., 1998). In addition, a post-entry block in
DMs may further limit productive infection by CXCR4-
ropic viruses (Verani et al., 1998).
Several studies have challenged the notion that CD4
nd CCR5 expression are sufficient for MDM infection.
heng-Mayer and co-workers (Cheng-Mayer et al., 1997)
eported that the SF2 isolate efficiently utilizes both
XCR4 and CCR5, but a reporter virus carrying this
nvelope did not productively infect MDMs. Dittmar and
olleagues (Dittmar et al., 1997) also reported a discrep-
ncy between coreceptor utilization and cellular tropism.
ato and co-workers (Kato et al., 1999) recently reported
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278hat some CCR5-tropic V3 mutants did not productively
nfect MDMs.
The viral component for coreceptor selectivity resides
ithin the envelope protein of HIV-1 (Bieniasz et al., 1997;
occhi et al., 1996). In particular, the third hypervariable
oop (V3) is a critical determinant of coreceptor utiliza-
ion. In addition, sequences surrounding the V3 loop are
mportant in coreceptor utilization (Kwong et al., 1998;
izzuto et al., 1998; Wyatt et al., 1998). These determi-
ants may contribute directly to coreceptor binding or
hey may alter the presentation of the V3 loop for optimal
inding or conformational alterations occurring after co-
eceptor interaction.
CCR5 is the primary coreceptor for viruses capable of
nfecting macrophages (Alkhatib et al., 1996; Choe et al.,
996; Deng et al., 1996; Dragic et al., 1996). Both ADA and
F162 productively infect macrophages, which also uti-
ize CCR5. However, SF2 virus, which uses CCR5 effi-
iently, does not productively infect macrophages
Cheng-Mayer et al., 1997). We have previously reported
ome V3 loop chimeric viruses capable of using CCR5 as
coreceptor. To investigate the relationship between the
se of CCR5 and MDM infection, we examined the ability
f these chimeric viruses to enter and productively infect
DMs. In addition, this study also investigated the sen-
itivity of these viruses to neutralization by an anti-CCR5
ntibody.
RESULTS
3 loop chimeric viruses
We have previously constructed a series of molecular
lones containing chimeric V3 loop sequences between
XB2 and ADA. Using these V3 loop chimeric viruses, we
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279MACROPHAGE INFECTION AND CCR5 TROPISMdentified residues within V3 important for CCR5 interac-
ions (Hung et al., 1999). The V3 loop sequences of some
f the chimeric viruses, ADAV3, V3B, YEIDI, EIDI and EII
re shown in Fig. 1. All of these viruses utilize CCR5 as
heir coreceptor and infected CD4/CCR5 expressing
eLa cells to similar levels (Hung et al., 1999). Virus
enerated from ADAV3 proviral DNA productively infects
uman PBMCs, and it contains sufficient determinants to
nfect MDMs (Henkel et al., 1995). Two other chimeras
lso were generated in which the V3 loop of NLHX was
eplaced with that of either SF2 or SF162 isolates, clones
F2V3 and SF162V3, respectively (Fig. 1). SF2 can utilize
oth CXCR4 and CCR5, whereas SF162 uses only CCR5
Cheng-Mayer et al., 1997). Both viruses infected CD4/
CR5-expressing HeLa cells (Hung et al., 1999) at levels
hreefold higher than that of the HXB2/ADA chimeras.
one of these viruses infected HeLa/CD4 cells in the
bsence of CCR5.
nfection of PBMCs and MDMs by V3 chimeras
All of the molecular clones tested displayed efficient
eplication in primary human PBMCs (Fig. 2). NLHX, the
arental virus, did not productively infect MDMs (Fig. 2A).
s reported previously, ADAV3 contained the determi-
ant for macrophage infection and was shown to pro-
uctively infect MDMs (Fig. 2B). SF162V3, similar to
FIG. 1. Chimeric virus constructs and their V3 loop sequences. The n
ccording to ADA envelope (Westervelt et al., 1991). NLHX virus is CXDAV3, showed efficient replication in MDMs (Fig. 2H). dowever, despite their ability to infect PBMCs and utilize
CR5, none of the other chimeric viruses was capable of
roductively infecting MDMs throughout the course of
nfection (Figs. 2C–2G). Results from multiple experi-
ents are summarized in Table 1. All viruses achieved
imilar levels of replication in PBMCs, ranging from
100- to 300-fold over the background level as deter-
ined by RT activity. Only SF162V3 and ADAV3 consis-
ently infected MDMs, ranging from 50- to 110-fold over
he background. Several viruses containing chimeric V3
oops with residues from SF2 and SF162, all of which are
CR5-tropic, also were examined, and none of them was
ble to infect MDMs (data not shown). These results
eaffirmed that the V3 loop contains the major determi-
ant for macrophage cellular tropism. They also sug-
ested that the utilization of the CCR5 coreceptor does
ot guarantee the ability to productively infect MDMs.
CR analysis of infected macrophages
We questioned whether the inability of one of the
CR5-tropic chimeras, V3B, to productively infect MDMs
as due to a block in the entry event. Therefore viral
ntry into MDMs was examined by polymerase chain
eaction (PCR).
The PCR assay sensitivity was established using
LHX proviral plasmid DNA diluted in uninfected, 7-day-
s above the sequences indicate the positions of amino acid residues
pic, whereas the others utilize CCR5 as their coreceptor.umberifferentiated MDM cell lysates, to the indicated copy
n
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280 HUNG, PONTOW, AND RATNERumber. As shown in Fig. 3A, the PCR sensitivity ranged
etween 500 and 5000 copies of proviral DNA. Amplifi-
ation of 1000 copies of HIV-1 was reliably detected (data
FIG. 2. PBMC and macrophage infections by the chimeric viruses.
nfections by NLHX (A), ADAV3 (B), V3B (C), YEIDI (D), EIDI (E), EII (F
eviations of the mean values obtained from duplicate samples.ot shown). PCR reactions were not affected by either ihe presence of detergent in the cell lysate nor additional
ellular DNA (data not shown).
PCR reactions with mitochondrial DNA control primers
anel shows the levels and kinetics of both PBMC (E) and MDM (N)
V3 (G), and SF162V3 (H). The error bars represent sample standardEach p
), SF2ndicated similar amounts of input DNA in each reaction
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281MACROPHAGE INFECTION AND CCR5 TROPISMFig. 3B). At day 0 p.i., no amplification of HIV-1 proviral
NA was detectable in any MDM culture (Fig. 3B). A
oninfectious virus derived from NLHX, NLHXDV3, used
s a negative control for infection, contained an in-frame
eletion of the C-terminal portion of the V3 loop. Both
ock-infected MDMs and NLHXDV3-infected cells were
egative by the PCR assay throughout the course of
nfection. Thus positive DNA signals are due to virus
ntry and reverse transcription not residual proviral plas-
id DNA or DNA incorporated into virus particles.
Entry of ADAV3 and SF162V3 into MDMs was readily
etectable by day 2 p.i. (Fig. 3B, D2). Addition of 2D7
esulted in minor reductions of entry. Inhibition of viral
ntry by 2D7 was more prominent by day 7 p.i. (Fig. 3B,
7). A very low level of viral entry by V3B chimeric virus
as detected by day 7 p.i. but not at earlier time points.
hese data suggest that V3B, although able to enter
DMs, could not do so effectively. Similar to previous
eports, an extremely low level of entry by NLHX parental
irus was detected at day 7 p.i. (Schmidtmayerova et al.,
998; Verani et al., 1998).
ACS analysis of surface molecules
To compare levels of CD4, CCR5, and CXCR4 present
t the surface of MDMs, MAGI, and MAGI-CCR5, cells
ere subjected to flow cytometry after indirect immuno-
luorescent staining (Fig. 4). Isotype-matched control IgG
taining yielded low median fluorescence intensity val-
es ranging from 4.5 to 8.7 for all three cell types. The
TABLE 1
Infection of PBMC and Macrophages
Virus
Infection
Levelb Virus
Infection
Levelb
BMC Infectiona
NLHX 208 6 60 SF162V3 303 6 15
ADAV3 281 6 45 SF2V3 362 6 29
V3B 98c
YEIDI 270c
EIDI 192 6 1
EII 299 6 19
acrophage Infectiond
NLHX 1 6 0 SF162V3 51 6 33
ADAV3 112 6 72 SF2V3 1 6 0
V3B 2c
YEIDI 2 6 1
EIDI 1 6 0
EII 1 6 0
Note. All results are calculated from two or more independent ex-
eriments except the indicated virus.
a PBMC infection: RT measured at days 11–13 p.i.
b Values represent the average fold increase over mock infection as
easured by RT activity.
c Results from one experiment.
d Macrophage infection: RT measured at days 15–23 p.i.edian fluorescence intensity for both CD4 and CXCR4 bFIG. 3. PCR analysis of viral entry into primary human macro-
hages. (A) Control PCR reactions for sensitivity and specificity.
LHX proviral DNA plasmids are diluted in uninfected macrophage
ysate to specified copy number as PCR standards. “LTR” indicates
CR results with primer pairs for the R/U5 region of HIV-1 LTR. “Env”
ndicates PCR results with primer pairs for the envelope gene. “Mito”
enotes PCR results with primer pairs for mitochondrial DNA. PCR
nalysis of mitochondrial DNA was used as internal control to
ontrol for the amounts of total DNA in PCR reactions. All three sets
f primers showed no background DNA amplification. (B) Entry of
IV-1 into macrophages. Three time points are shown in this figure.
D0” denotes cells assayed at the time of infection. Cells with viral
noculum were incubated on ice for 10 min before harvest. “D2” and
D7” are cells assayed at 2 and 7 days p.i., respectively. “LTR,” “Env,”
nd “Mito” denotes the same PCR products as in (A). Infections were
erformed in duplicate wells. PCR analysis revealed little difference
etween duplicate cultures.
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282 HUNG, PONTOW, AND RATNERtaining was increased .10-fold in MAGI-CCR5 and
AGI cells relative to MDMs. Median fluorescence in-
ensities obtained following specific labeling of CCR5
as 28-fold greater for MAGI-CCR5 cells than for MDMs.
imilar results were obtained with two other anti-CCR5
Abs, one against an epitope of the second extracellular
oop and another directed against the CCR5 N terminus
data not shown). MAGI cells were negative for CCR5
taining.
esistance to anti-CCR5 antibody neutralization
To further characterize the interaction of chimeric vi-
uses with CCR5, the sensitivity of CCR5 usage to anti-
ody neutralization was examined. The MAGI-CCR5 in-
icator cell line (Hung et al., 1999) was utilized to detect
CR5-mediated infection. Cells were pretreated with an-
ibodies as described in Materials and Methods and
nfected with viral stocks normalized for p24 content.
NLHX virus infected both MAGI and MAGI-CCR5
FIG. 4. Flow cytometirc analysis of cell surface CD4, CCR5 and CXC
ntibodies is shown in thick lines. The reactivity of isotype-matched con
luorescence intensity obtained with each experimental antibody is givells, indicating that it entered these cells via CXCR4 AHung et al., 1999). Infection of MAGI-CCR5 cells by
LHX was not inhibited by 2D7 antibody to a signifi-
ant extent (Fig. 5). The nonneutralizing antibody, 5C7,
lso did not inhibit the infection; enhancement was
bserved. When 10 mg/ml of the neutralizing antibody,
D7, was first incubated with the cells, infection of
AGI-CCR5 cells by ADAV3, V3B, YEIDI, EIDI, and EII
as inhibited (Fig. 5). Although no infection was de-
ected by V3B, YEIDI, EIDI and EII in the presence of
D7, this antibody only inhibited ADAV3 infection by
0%. MAb 5C7 also recognizes CCR5 but did not neu-
ralize the infection by any CCR5-tropic viruses. These
esults suggest that the inhibition seen with 2D7 in-
eed was not due to nonspecific binding of 2D7 but
ather blocking the accessibility to the coreceptor.
We had previously reported the dose effect of 2D7
eutralization profiles of ADAV3, V3B, YEIDI, EIDI, and EII
Hung et al., 1999) (Fig. 6A). Chimeric viruses V3B, EIDI,
nd EII were more sensitive to 2D7 neutralization than
pressed on MDM and MAGI cell lines. The reactivity of experimental
ibodies is indicated by thin line in each panel. Value of specific median
pper right corner of each panel.R4 ex
trol antDAV3. We examined the sensitivity of SF2V3 and
S
i
A
1
w
S
a
6
t
m
t
f
d
a
t
t
m
s
c
i
H
t
a
t
C
(
t
a
a
i
283MACROPHAGE INFECTION AND CCR5 TROPISMF162V3 chimeras to 2D7 inhibition. Although SF2V3
nfected MAGI-CCR5 cells to much higher level than
DAV3 and other HXB2/ADA chimeras (Hung et al.,
999), it showed high sensitivity to 2D7 neutralization—
ith 88% inhibition at 0.4 mg/ml (Fig. 6B). Conversely,
F162V3 was relatively resistant to 2D7 neutralization
nd exhibited a similar inhibition profile as ADAV3 (Fig.
B). Interestingly, both ADAV3 and SF162V3 also produc-
ively infect MDMs.
These data demonstrated that although all of the chi-
eric viruses tested could utilize CCR5 efficiently as
heir coreceptor on an indicator cell line, they have dif-
erent sensitivity to 2D7 neutralization. This might reflect
ifferences in their interaction with the coreceptor. In
ddition, we observed a correlation between the ability
o productively infect macrophages and relative resis-
FIG. 5. Neutralization of inance to 2D7 neutralization. 2DISCUSSION
Many members of the G-protein-coupled, seven-trans-
embrane-domain protein family have been found to
erve as coreceptors for HIV and/or SIV. CCR5, the re-
eptor for b-chemokines RANTES, MIP-1a, and MIP-1b,
s the primary coreceptor for the majority of primary
IV-1 isolates (Doms and Moore, 1997). CCR5 serves as
he major coreceptor on macrophages for HIV-1 (Rana et
l., 1997; Naif et al., 1998; Tuttle et al., 1998). Residues in
he V3 loop of the HIV-1 envelope protein critical for
CR5 utilization were identified with chimeric viruses
Hung et al., 1999). To understand the relationship be-
ween CCR5 utilization and macrophage infection, the
bility of these chimeric viruses to infect human PBMCs
nd MDMs was assessed. All of the chimeric viruses
nfected PBMCs efficiently and with similar kinetics (Fig.
by anti-CCR5 antibodies.fectionand Table 1), suggesting that substitutions within the
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284 HUNG, PONTOW, AND RATNER3 loop did not significantly affect the function of the
nvelope protein. However, productive infection of
DMs occurred only with ADAV3 and SF162V3 (Figs. 2B
nd 2H and Table 1), viruses including the entire V3 loop
rom macrophage-tropic isolates. The other chimeric vi-
uses, although able to utilize CCR5 for entry, did not
roductively infect MDMs. These results suggested
CR5 usage is not sufficient for macrophage tropism.
Although CCR5 has been implicated as the primary
oreceptor for macrophage infection, CXCR4, also ex-
ressed on MDMs, can mediate HIV-1 entry (Schmidt-
FIG. 6. 2D7 neutralization of infection. (A) Infection of MAGI-CCR5
ells by HXB2/ADA chimeras in the presence of 2D7 antibody (Hung et
l., 1999). All viruses exhibited dose dependent sensitivity to 2D7
eutralization. ADAV3 virus was more resistant to inhibition by this
ntibody compared to others. Reprinted with permission from J. Virol.
B) Infection of MAGI-CCR5 cells by SF2V3 and SF162V3 viruses in the
resence of 2D7 antibody. SF162V3, unlike SF2V3, was relatively resis-
ant to 2D7 inhibition. Error bars indicate the sample standard devia-
ions of the mean values obtained from duplicate samples. Represen-
ative data from multiple experiments is presented here.ayerova et al., 1998; Simmons et al., 1998; Verani et al., i998; Yi et al., 1998), but this results in a nonproductive
nfection due to a defect in nuclear translocation of the
reintegration complex. Thus, coreceptor selectivity in-
luences postentry events in HIV-1 replication. Although
ll viruses used in the current study utilize CCR5 effi-
iently, their interaction with the coreceptor might be
ifferent. The differences in the envelope-coreceptor in-
eraction could influence infections by these viruses. For
ome chimeric viruses, the block in infection could occur
t the entry, reverse transcription, or subsequent nuclear
ransport steps. The current data indicated that V3B, a
CR5-tropic chimera that did not productively infect
DMs, exhibited a marked reduction in entry into MDMs
s assayed by PCR for viral reverse transcription prod-
cts (Fig. 3B). This suggested that the defect occurred at
he entry step. We could not, however, exclude the pos-
ibility that there also might be defects in the postentry
vents.
Several explanations could account for the dichotomy
etween CCR5 utilization and macrophage infection. Dif-
erences in the surface expression levels of both CD4
nd CCR5 on MDMs may be critical. Different HIV-1
solates exhibit differences in threshold requirements for
urface expression of CD4 and CCR5 (Kozak et al., 1997;
latt et al., 1998). Chimeric viruses V3B, YEIDI, EIDI, EII,
nd SF2V3 might have higher threshold level require-
ents for CD4 and/or CCR5 compared with ADAV3 and
F162V3. MAGI-CCR5 cells used in the present study
xpress high levels of both CD4 and CCR5 (Hung et al.,
999), which may be sufficient for infection by all the
iruses tested. Results from the FACS analysis indicated
hat the levels of CD4 and CCR5 expression were 10- and
8-fold lower, respectively, on MDMs than MAGI-CCR5
ells (Fig. 4). The lower level of CD4 and CCR5 expres-
ion on the MDMs could have been sufficient for infec-
ion by ADAV3 and SF162V3 but not for the other chime-
as. This is consistent with the 2D7 antibody study that
howed that macrophage-tropic isolates showed partial
esistance to neutralization (Figs. 5 and 6).
The presentation of chemokine receptors on various
ell types also may be qualitatively different. CCR5 is
hought to be expressed in different conformational
orms (Hill et al., 1998; Lee et al., 1999). Differences in
osttranslational modifications may account for alter-
tions of coreceptor conformation. CCR5 has four con-
erved cysteines in the extracellular domains which form
wo intramolecular disulfide bonds (Berson and Doms,
998). CCR5 has one potential N-linked glycosylation
ite. Tyrosine residues on the N terminus of CCR5 have
een shown to be sulfated (Farzan et al., 1999). In addi-
ion, chemokine receptors exist in a dimerized or oli-
omerized form (Benkirane et al., 1997).
A third possibility is that there may be different models
f interaction with the coreceptor for different chimeric
nvelopes. Studies of regions of CCR5 important fornfection by HIV-1 have yielded variable results (Alkhatib
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285MACROPHAGE INFECTION AND CCR5 TROPISMt al., 1997; Bieniasz et al., 1997; Ross et al., 1998).
himeric coreceptors containing portions of CCR5 with
ther chemokine receptors indicated that HIV-1 strains
xhibited distinct requirements for different regions of
CR5. The ADA virus can efficiently infect cells express-
ng human/murine chimeric CCR5 containing any extra-
ellular loop of the human receptor, whereas BaL (CCR5-
ropic) or 89.6 (dual-tropic) have more stringent require-
ents. If the ADAV3 chimeric virus behaves similar to the
DA virus, 2D7, blocking the accessibility to the second
xtracellular loop, would be predicted to have minimal
nfluence on infection (Figs. 5 and 6A). On the other hand,
ome of the chimeras may have lost the promiscuity for
he use of the different coreceptor domains, and they
ay exhibit higher specificity for a single binding site,
.e., the second extracellular loop. This would suggest
hat the second extracellular loop of CCR5 on MDMs
ay form a distinct conformation compared with that on
BMCs. It is interesting to note that while 2D7 inhibited
hemotatic activity of b-chemokines on various cell
ypes, it did not inhibit blood monocyte chemotatic re-
ponse (Wu et al., 1997a). Alternatively, the exclusive
tilization of a single binding site might lower their over-
ll affinity for CCR5 and reduce their ability to infect
acrophages expressing low level of CCR5.
CCR5 associates with CD4 on the cell surface. MAb
D7 binding could have disrupted such an interaction,
educing the level of CD4-CCR5 complexes. Although the
D4 binding site on gp120 maps outside of the V3 loop,
utations in V3 loop have been shown to affect either
he association of gp120 with CD4 or sensitivity of HIV-1
o soluble CD4 (sCD4) neutralization (Hwang et al., 1992;
hoe and Sodroski, 1995). The V3 loop sequence
hanges in the chimeric viruses might have inadvertently
ffected the affinity of these chimeric envelopes with
D4. Some chimeras might be more dependent on the
evel of CD4 and therefore are more sensitive to 2D7
nhibition and do not productively infect MDMs due to the
educed level of available CD4 in the CD4-CCR5 com-
lex.
Infection of macrophages plays an important role in
IV-1 transmission and pathogenesis (Crowe, 1995;
osier and Sieburg, 1994; Schuitemaker, 1994). Uncov-
ring the envelope determinants critical for macrophage
nfection may provide a potential vaccine or treatment. In
he absence of a complete tertiary structure of HIV-1
p120, it poses a major challenge to identify a conserved
equence determinant for macrophage tropism (Chese-
ro et al., 1992). There are convincing data supporting
he notion that CCR5 serves as an important coreceptor
n macrophages. However, the ability to utilize CCR5 as
he coreceptor is not sufficient for efficient replication in
acrophages. Our report suggests that other factors
lso contribute to the ability of a virus to productively
nfect macrophages. The surface concentrations of CD4
nd/or CCR5 molecules on macrophages might play an important role. Alternatively, a conserved functional de-
erminant, as revealed by 2D7 neutralization study, rather
han linear sequences, plays a role in productive mac-
ophage infection.
MATERIALS AND METHODS
ntibodies
Two CCR5 monoclonal antibodies (mAbs) used in this
tudy, 2D7 and 5C7, were obtained through the AIDS
esearch and Reference Reagent Program, Division of
IDS, NIAID, NIH (provided by LeukoSite, Inc.). MAb 2D7
pecifically recognizes the second extracellular loop of
CR5. The epitope of mAb 5C7 maps to the N terminus
f CCR5 (Wu et al., 1997b). A third mAb directed against
he second extracellular loop of CCR5 was purchased
rom R & D Systems. Anti-CXCR4 mAb, 12G5, was ob-
ained through the AIDS Research and Reference Re-
gent Program. Anti-CD4 mAb and isotype-matched con-
rol IgGs were purchased from PharMingen. R-phyco-
rythrin-conjugated goat-anti-mouse IgG was purchased
rom Calbiochem.
ells and cell lines
The human embryonic kidney cell line, 293T, were
aintained in Dulbecco’s modified Eagle’s medium sup-
lemented with 10% fetal bovine serum (GibcoBRL), 1
M pyruvate [WUMS Tissue Culture Support Center
TCSC), St. Louis, MO], 2 mM L-glutamine (WUMS TCSC),
00 U/ml pen/100 mg/ml strep (WUMS TCSC) (complete
MEM). Human PBMCs from HIV-1 negative blood do-
ors were isolated by Ficoll–Hypaque (Sigma, St. Louis,
O) gradient centrifugation and stimulated with 10
g/ml PHA (Difco, Detroit, MI) for 3 days. Activated
BMCs were maintained in RPMI 1640 medium (Gibco-
RL, Grand Island, NY) supplemented with 10% fetal
ovine serum, 4 mM L-glutamine, 100 U/ml pen/100
g/ml strep, and 50 U/ml interleukin-2 (IL-2; gift from
etus, Chiron Therapeutics, Emeryville, CA) (PBMC me-
ium). Human MDMs from healthy HIV-1 negative donors
ere obtained by countercurrent elutriation and were
ultivated in Iscove’s modified Dulbecco’s medium sup-
lemented with 10% human serum (BioCell, CA), 4 mM
-glutamine (BioWhittaker, Walkersville, MD), 100 U/ml
en/100 mg/ml strep, and 500 U/ml recombinant M-CSF
MDM medium). MAGI cells were maintained in com-
lete DMEM supplemented with 200 mg/ml Geneticin
GibcoBRL, Grand Island, NY), and 100 mg/ml hygromy-
in (Boehringer Mannheim, Indianapolis, IN) (MAGI me-
ium). MAGI-CCR5 cells were propagated in MAGI me-
ia plus 0.25 mg/ml puromycin (Sigma) (MAGI-CCR5 me-
ia).
low cytometry analysis
All antibody incubations and washes were performed
n PBS containing 5% fetal bovine serum, 5% human AB
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286 HUNG, PONTOW, AND RATNERerum (BioWhittaker), and 5% rabbit serum (Calbiochem)
t 4°C. Cells (1 x 106) were incubated with 1 mg of
onoclonal antibody directed against CD4, CCR5, or
XCR4 and washed. A second incubation with R-phyco-
rythrin-conjugated anti-mouse IgG was followed by ex-
ensive washing and fixation in 1% paraformaldehyde.
ell surface labeling was detected using a FACScan
Becton Dickinson, Mountain View, CA) and analyzed
ith CellQuest software. Specific median fluorescence
ntensity was determined by subtracting the value ob-
ained with an isotype-matched control IgG from the
alue obtained with the experimental primary IgG.
eneration of viral stocks
Viral stocks were generated by transfection of 293T
ells. Transfection mixtures containing full-length provi-
al DNA and Lipofectamine (GibcoBRL, Gaithersburg,
D) were incubated overnight with 80% confluent 293T
ells in 100 mm plates. Transfection mixtures were as-
irated the next day and replaced with complete DMEM.
upernatants were harvested on the fourth day post-
ransfection. Following a 1000 g spin to discard cellular
ebris, the supernatants were passed through 0.22 mm
ilters, aliquoted and stored at 280°C. Viral titers were
etermined by p24 antigen ELISA assay (Coulter, Miami,
L). All viral stocks were first assayed on MAGI-CCR5
ells. In accordance with our previous report (Hung et al.,
999), chimeras ADAV3, V3B, YEIDI, EIDI, and EII all
nfected MAGI-CCR5 cells to the same levels at 2.5 ng
24 antigen equivalent of viral input, while SF2V3 and
F162V3 viruses infected these cells at levels threefold
igher.
nfection of PBMCs and MDMs
PHA stimulated PBMCs were seeded in 24-well plates
t 106 cells/well on the day of infection. Viral superna-
ants normalized to 90 ng p24 value were added to each
ell and adsorbed overnight. The next day, viral inocu-
ums were removed and replaced with PBMC medium.
nfection by each virus was performed in duplicate or
riplicate wells for each experiment. Culture superna-
ants were collected every 4–6 days, and levels of tri-
hloracetic acid-precipitatable reverse transcriptase ac-
ivity were assessed as an indirect measure of virus
roduction (Stanley and Fauci, 1993). Elutriated blood
onocytes were seeded in 24-well plates at 2 3 105
ells/well. The monocytes were allowed to differentiate
n vitro for $7 days before infection. Infections of MDMs
ere carried out in the same way as infection of PBMCs.
or each experiment, infections of PBMCs and MDMs by
ach viral clone were performed in parallel.
nhibition of infection
Antibody inhibition assays were performed according
o a modified MAGI-CCR5 infection method (Kimpton and Tmerman, 1992). Cells were seeded in 96-well plates. On
he following day, media were removed, and indicated
oncentrations of antibodies (in 50 ml volume) were
dded. Cells were incubated with antibodies for 1 h at
7°C and then 2.5 ng p24 equivalent of diluted viruses (in
0 ml) plus DEAE-dextran (final concentration of 20 mg/
l) were added without the removal of antibodies. MAGI-
CR5 media (100 ml) were added into each well at the
nd of absorption period. At 40–48 h p.i., cells were
ssayed for infection with chlorphenol red-b-D-galacto-
yranoside (CPRG; Boehringer Mannheim, Indianapolis,
N) (Nussbaum et al., 1994). Briefly, N-P40 detergent
Sigma) was added to each well to final concentration of
.5% to lyse the cells. A freeze–thaw step was performed
o ensure complete cell lysis. Lysate (50 ml; 1/4 of total
ell lysate) from each well was added to an equal volume
f 23 CPRG solution (10 mM CPRG, 120 mM Na2HPO4 3
H2O, 80 mM NaH2PO4 3 H2O, 20 mM KCl, 2 mM MgSO4
7H2O, and 100 mM b-mercaptoethanol), and the reac-
ion was incubated for 45 min at room temperature. The
mount of substrate hydrolysis, which reflected the level
f infection, was measured in an ELISA reader (BioTek
nstrument, Inc., Burlington, VT) at an optical density of
90 nm. Infection levels achieved in the absence of
ntibody for each virus were arbitrarily designated as
00%. Infection results obtained in the presence of anti-
ody are presented as percent inhibition of infection.
CR analysis of macrophage infection
Viral inoculums were treated with 200 U/ml RNase-
ree DNaseI (Sigma) for 1 h at room temperature to
nactivate plasmid DNA carried over from viral stock
eneration. Treated viruses were diluted in complete
MEM to equal p24 values for infection. Infection of
DMs was carried out as indicated above except for the
ay 0 (D0) time point when MDMs overlaid with viral
noculum were incubated on ice for 10 min. and then
ashed twice with PBS. All infections were carried out in
uplicate wells. Infections of MDMs by ADAV3 and
F162V3 also were performed in the presence of 2D7
ntibody, after preincubation of MDMs with 2 mg/ml 2D7
or 1 h at 37°C. Each well of MDMs was lysed and
reated with 0.2 mg/ml Proteinase K (GibcoBRL) at 57°C
vernight, then Proteinase K was heat inactivated at
00°C for 10 min.
Two sets of HIV-1-specific primers were used for PCR
etection of the HIV-1 proviral genome. Primers HIV1–25
nd HIV145–121(LTR primers) amplify the R/U5 portion
145 bp in length) of HIV-1 long-terminal repeats (LTR).
he LTR primers allow the detection of a very early step
f the reverse transcription. Primers JA10 and JA11 (Env
rimers) amplify 307 bp within the envelope gene and
etect later products of reverse transcription. A set of
itochondrial DNA primers (Wrischnik et al., 1987), MI-OA and MITOB (Mito primers), were used to control for
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287MACROPHAGE INFECTION AND CCR5 TROPISMhe amounts of total input DNA in each PCR reaction. The
equences of primers for PCR amplification are as fol-
ow:
HIV1–25 59-GGGTCTCTCTGGTTAGACCAGATCT-39;
HIV145–121 59-GGGATCTCTAGTTACCAGAGTCACA-39;
JA10 59-TTTGAATTCAGATCTGTCAATTTCACGGA-39;
JA11 59-TTTGAATTCGGGTCCCCTCCTGAGGATTG-39;
MITOA 59-ATGCTAAGTTAGCTTTACAG;
MITOB 59-ACAGTTTCATGCCCATCGTC-39.
Amplification of total cell lysate was performed in 20 ml
f PCR reaction mixture containing 10 mM Tris 3 HCl
pH 8.3), 50 mM KCl, 3 mM MgCl2, 0.25 mM each dATP,
CTP, dGTP, and dTTP, 200 pmol of each primer, and 1
nit Taq polymerase (GibcoBRL). In addition, each reac-
ion included 1 mCi of a[32P]dCTP (ICN, Costa Mesa, CA).
oth LTR and Env primers were used together in the
ame PCR reaction for detection of HIV-1 while the Mito
rimers were used in separate reactions as PCR control.
ll PCR amplifications were subjected to the following
onditions: 94°C 1 min, 62°C 2 min, and 72°C 3 min for
5 cycles with a single cycle 72°C 10-min extension step
t the end. Half of each PCR reaction was resolved on
2% nondenaturing, TBE–polyacrylamide gel and sepa-
ated PCR products were visualized by autoradiograph.
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